Takeda Pharmaceuticals North America, Inc. announced today that ULORIC(R) (febuxostat) is now available by prescription in pharmacies across the United States for the chronic management of hyperuricemia in patients with gout. Gout is a chronic condition that affects more than five million Americans. This once-daily oral medication, available in 40-mg and 80-mg tablets, is the first new treatment option for hyperuricemia in patients with gout in more than 40 years.
The details can be read here.
No comments:
Post a Comment